NAPSRx

Valeant Pharmaceuticals has received approval from the U.S Food and Drug Administration (FDA)  for ONEXTON™ Gel (clindamycin phosphate and benzoyl peroxide), 1.2%/3.75% for the once-daily treatment of Acne vulgaris in patients 12 and older.

According to the Decisions Resource Group sales of migraine therapies are projected to grow from $3 billion to over $5 billion in the United States, France, Germany, Italy, Spain, United Kingdom and Japan through 2023.

AstraZeneca plans to invest up to $200 million to increase manufacturing and production efforts at its biologics manufacturing center in Frederick, Maryland, US.

Hysingla ER is a once-daily opioid analgesic formulated with abuse-deterrent properties.

Sanofi and Regeneron’s investigational therapy, Dupilumab has received the Breakthrough Therapy Designation from the U.S.

Pfizer and Merck KGaA have announced plans to enter into an agreement to jointly develop and commercialize the investigational anti-PD-L1 antibody MSB0010718C developed by Merck KGaA to treat multiple forms of cancer.

Genzyme’s MS therapy, Lemtrada (alemtuzumab) has been approved by the U.S. Food and Drug Administration to treat patients with relapsing forms of multiple sclerosis (MS).

AstraZeneca and Amgen’s investigational psoriasis treatment brodalumab posted successful results from the AMAGINE-3TM multi-arm Phase III trial.

The U.S. Food and Drug Administration (FDA) has accepted for review, Amgen’s Biologics License Application (BLA) for evolocumab to treat high cholesterol.

The approval of Pfizer's Trumenba represents the first vaccine licensed in the United States to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.